Poster presentation at TIDES Asia 2024
Dr Tatsuo Ito, the founder of CLOVERNA, will have a poster presentation about our platform technology at TIDES Asia 2024 (March 19-21, 2024 in Kyoto, Japan). The detail of conference
CLOVERNA will have a company booth at JHVS 2023
At Japan Healthcare Venture Summit (JHVS) 2023 in Yokohama, Japan, CLOVERNA will have a company booth in JHVS area, V-60. Join us to discuss RNA targeted drug discovery! Information of
Continue readingCLOVERNA will have a company booth at JHVS 2023
CLOVERNA presents at RNA Assay Development & Screening Summit
Dr Tatsuo Ito, the founder of CLOVERNA, will make a presentation the RNA Assay Development & Screening Summit (August 23-24, 2023 in Boston, US). The title of presentation is “Unlocking
Continue readingCLOVERNA presents at RNA Assay Development & Screening Summit
Announcement of publication of the research of non-coding region in SARS-CoV-2
Scientific publication of the research of non-coding region in SARS-CoV-2 with CLOVERNA’s technology was published in Scientific Reports. Detail of publication is below. An RNA-immunoprecipitation via CRISPR/dCas13 reveals an interaction
Continue readingAnnouncement of publication of the research of non-coding region in SARS-CoV-2
Japanese Bio StartUp CLOVERNA announces a pre-seed round by VC in Tokyo
The pre-seed round was funded by Keio Innovation Initiative, Inc. and backed CLOVERNA’s first raise. CLOVERNA is a revolutionary RNA target drug discovery technology to accelerate the rare disease treatment
Continue readingJapanese Bio StartUp CLOVERNA announces a pre-seed round by VC in Tokyo
The BioLabs JETRO Kyoto Startup-City Acceleration Program in Boston
We, CLOVERNA, were honored to participate in the BioLabs JETRO Kyoto StartUp-City Acceleration Program. BioLabs and JETRO USA provided a one-week program by talking about the importance of innovation and international
Continue readingThe BioLabs JETRO Kyoto Startup-City Acceleration Program in Boston